Does early cryoballoon ablation reduce arrhythmia recurrence, mortality, or heart failure hospitalization in heart failure patients with atrial fibrillation compared to delayed ablation?
Early cryoballoon ablation (within 6 months of diagnosis) for atrial fibrillation in heart failure patients significantly reduces the risk of arrhythmia recurrence compared to delayed ablation, though it does not impact mortality or heart failure hospitalization.
Background: Atrial fibrillation (AF) and heart failure (HF) often coexist, leading to increased mortality. A cryoballoon-based approach is a potential treatment for patients with HF because of its safety and efficacy. Objectives: The authors sought to evaluate the optimal timing of cryoballoon ablation after the first clinical diagnosis of AF and its prognosis for patients with HF. Methods: This large-scale multicenter study retrospectively collected data of patients with HF who underwent cryoballoon ablation for AF from 17 Japanese institutions. Patients were divided into 2 groups depending on the duration between the first diagnosis and ablation using a median time of 0.5 year (IQR: 0.3-2.0 years). Clinical endpoints of recurrence, mortality, and HF hospitalization were compared between the 2 groups. Results: = 0.004). Delayed time for cryoballoon ablation incrementally increased the risk of postablation recurrence. Antiarrhythmic drug use was independently associated with delayed ablation. No significant differences in mortality or HF hospitalization were observed between the 2 groups. Conclusions: Early cryoablation reduced the risk of recurrence in patients with HF, which may help improve clinical management.
Ando et al. (Tue,) studied this question.